Rosen Comments on Benefits of More FDA-Approved Generic Drugs

31 January 2018 Health Care on Bloomberg Law News
Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions,” about the FDA approving a record number of generic drugs in 2017 amid speculation that President Trump doesn’t want to lower prescription drug prices.

Rosen said it’s encouraging that drug pricing and generic drugs are on Trump’s mind. He explained that generic drugs “can certainly hold down health-care costs” by giving people access to products that are high quality, therapeutically equivalent and lower cost, and that FDA Commissioner Scott Gottlieb is working to make generic drugs more accessible and to ensure applications are approved in a timely manner.

Related Services

Insights

RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
DHS Moves Closer to Launching its H-1B Cap Registration System
16 September 2019
Labor & Employment Law Perspectives
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.